Clinical trial
Miltefosine (Long Course) for Bolivian Mucosal Leishmaniasis
NCT00373568 · AB Foundation, Other · Completed
Key facts
| NCT number | NCT00373568 |
|---|---|
| Title | Miltefosine (Long Course) for Bolivian Mucosal Leishmaniasis |
| Official title | Miltefosine (42 Days) for Mucosal Leishmaniasisi |
| Lead sponsor | AB Foundation, Other |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Leishmaniasis |
| Intervention type | Drug |
| Interventions | miltefosine: 2.5 mg/kg/day for 42 days |
| Enrollment | 25 |
| Start date | Apr 1, 2005 |
| Completion | Dec 1, 2007 |
| First posted | Sep 8, 2006 |
| Last update posted | Jun 2, 2010 |
| Countries | Bolivia |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: